Cytarabine hydrochloride
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Cytarabine hydrochloride
- Molecular weight
- 279.68
- Structure (SMILES)
- Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
- 1 beta d arabinofuranosylcytosine monohydrochloride
- 1-.BETA.-D-ARABINOFURANOSYLCYTOSINE MONOHYDROCHLORIDE
- 2 1h pyrimidinone 4 amino 1 beta d arabinofuranosyl monohydrochloride
- 2(1H)-PYRIMIDINONE, 4-AMINO-1-.BETA.-D-ARABINOFURANOSYL-, MONOHYDROCHLORIDE
- cytarabine hcl
- Cytarabine hcl
- cytarabine hydrochloride
- Cytarabine hydrochloride
- CYTARABINE HYDROCHLORIDE [USAN]
- Cytarabine hydrochloride [WHO-DD]
- cytarabine hydrochloride usan
- cytarabine hydrochloride who dd
- cytosine arabinoside
- Cytosine arabinoside
- Cytosine Arabinoside
- cytosine arabinoside hydrochloride
- Cytosine arabinoside hydrochloride
- nsc 63878
- NSC-63878
- u 19920a
- U-19920A
- ATC classification codes
- L01BC01
Sources for recorded values
- CAS registry numbers
- 69-74-9
- ChEMBL ID
- CHEMBL1256472
- InChIKey
- KCURWTAZOZXKSJ-JBMRGDGGSA-N
- RxNorm IDs (RxCUI)
- 3041
- FDA ingredient codes (UNII)
- 33K3DB6591
- 6252
- 74764111
- 167312617
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -arabine
Open Targets mechanisms
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
- Action type
- Inhibitor
- Target
- DNA polymerase (alpha/delta/epsilon)
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Leukemia
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Leukemia, Myeloid
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004643
- Subject identifier
- D007951
- Condition identifier
- EFO_0000222
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0018876
- Highest recorded phase
- 2
- Warning
- Black Box Warning
- Effect
- gastrointestinal toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- hematological toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- hepatotoxicity
- Country
- United States
- Event
- aplasia
- Reports
- 2
- Reporting signal score
- 8.41969
- Event
- bone marrow failure
- Reports
- 25
- Reporting signal score
- 114.373
- Event
- granulocyte count decreased
- Reports
- 2
- Reporting signal score
- 9.69765
- Event
- myelosuppression
- Reports
- 4
- Reporting signal score
- 13.3549
- Event
- white blood cell count decreased
- Reports
- 6
- Reporting signal score
- 10.1631
- NCT00146120
- NCT04220684
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 4
- Polar surface area
- 130.83
- Calculated partition coefficient (ALogP)
- -2.56
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 18
- Molecular formula
- C9H14ClN3O5
- Monoisotopic mass
- 279.0621982
- Natural product
- No
- Recorded assays
- 1,271
- Active assays
- 50
- Confirmatory
- Other
- Screening
- Summary
- Antimetabolites, Antineoplastic
- Antiviral Agents
- Immunosuppressive Agents
Related records
Trials (1,096)
- [CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children
- 3-AP and Cytarabine in Treating Patients With Hematologic Cancer
- 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies
- 506U78 in Treating Patients With Refractory Hematologic Cancer
- 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome
- A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia
- A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment
- A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation
- A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
- A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
- A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
- A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia
- A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML)
- A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
- A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
- A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
- A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias
In development for (3)
- Acute myeloid leukemia Phase 3
- Leukemia Phase 1
- Myeloid leukemia Phase 1